ClinicalTrials.gg
Not yet recruitingNCT07913048Updated Nov 3, 2026

A Study to Evaluate the PK/PD and Safety of KL0011034 Injection in Healthy Non-Elderly and Elderly Trial Participants

A Phase 1 interventional study of KL0011034 injection in Healthy Participants, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

Updated Nov 3, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the pharmacokinetic characteristics of a single intravenous injection of KL0011034 injection in healthy non-elderly and elderly trial participants.

To evaluate the pharmacodynamics and safety of a single intravenous injection of KL0011034 injection in healthy non-elderly and elderly trial participants.

Read the detailed description

This study is a single-center, non-randomized, open-label, parallel study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of a single dose of KL0011034 injection in healthy non-elderly and elderly trial participants.

The study plans to enroll 20 trial participants, who will be assigned to the elderly group and the non-elderly group, with 10 participants in each group. After signing the informed consent form, all trial participants will undergo screening from D-14 to D-2 according to the procedures specified in the protocol. Trial participants who successfully pass screening will be admitted to the study site on Day -1 (D-1) before dosing to complete the procedures specified in the protocol. On Day 1 (D1), all trial participants will receive a single intravenous infusion of the investigational drug (KL0011034 injection), and PK blood sampling, pharmacodynamic, and safety evaluations will be performed. After completing the corresponding laboratory tests and assessments on Day 2 (D2) and upon confirmation by the investigator, participants may be discharged from the study.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Participants
03

In context

Lead sponsor

Hunan Kelun Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Non-Elderly Trial Participants (Age≥ 18 years and \<65 years),Healthy Elderly Trial Participants(Age≥ 65 years );
  2. Body Weight: Male≥50.0kg, Female≥45.0kg; 19.0 ≤≤ 28.0;
  3. From ICF signing to 3 months post-last dose: no conception plans (participant/partner), no sperm/egg donation, effective for 3 months post-last dose; no unprotected sex within 2 weeks pre-dose.;

Exclusion criteria

Exclusion Criteria:

  1. Allergy or Drug ;
  2. Medical History;
  3. History of anesthesia accident, history of serious adverse reactions of anesthesia, or family history of anesthesia accidents, or to general anesthesia;
  4. Dyspnoea or suspected difficult airway, or predicting difficult endotracheal intubation;
  5. History of bronchial asthma, , sleep apnea syndrome;
  6. History of adrenal insufficiency or adrenal tumor or hereditary heme biosynthesis disorder or hereditary acute porphyria;
  7. Physical examination, vital signs, 12-lead , posterior-anterior chest radiograph, abdominal ultrasound examination, and abnormal laboratory test results;
  8. Elderly group: SBP ≥160 mmHg and/or DBP ≥100 mmHg; non-elderly group: SBP ≥140 mmHg and/or DBP ≥90 mmHg ;
  9. History of any surgery within 3 months;
  10. History of any Medication within 14 days;
  11. History of any clinical study within 3 months;
  12. History of any vaccine within 1 month;
  13. History of any drug abuse;
  14. Needle sickness, Hematosickness;
  15. Massive blood loss (> 400 mL) in the past 3 months;
  16. Female volunteers are pregnant or lactating;
  17. Heavy smoker ( more than 5 cigarettes/day) within 3 months;
  18. History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months;
  19. Heavy caffeine intake;
  20. History of grapefruit, xanthine-rich foods intake within 48 hours;
  21. Positive alcohol test;
  22. Positive nicotine test;
  23. Positive drugs of abuse test result.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Elderly group

    Ten elderly Trial Participants will receive KL0011034 injection

    Drug: KL0011034 injection

  • Experimental
    Non-Elderly group

    Ten non-elderly Trial Participants will receive KL0011034 injection;

    Drug: KL0011034 injection

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameter Cmax in plasma

    Maximum peak plasma concentration (Cmax) of KL0011034 .

    Time frame: 24 hours post-dose for each period

  2. PK parameter Tmax in plasma

    Time of Cmax (Tmax) of KL0011034 .

    Time frame: 24 hours post-dose for each period

  3. PK parameter AUC0-t in plasma

    Area under the concentration-time curve (AUC0-t) from time zero to time "t" of KL0011034 .

    Time frame: 24 hours post-dose for each period

  4. PK parameter AUC0-∞ in plasma

    AUC from time zero to infinity (AUC0-∞) of KL0011034

    Time frame: 24 hours post-dose for each period

  5. PK parameter t1/2 in plasma

    Terminal-phase elimination half-life (t1/2) of KL0011034 .

    Time frame: 24 hours post-dose for each period

Secondary outcomes

  1. Modified Observer's Assessment of Alertness Sedation (MOAA/S) scale

    MOAA/S is a commonly used clinical sedation assessment scale, ranging from 0 to 5, which helps clinicians determine the level of sedation in patients. A score of 5 indicates full consciousness, whereas a score of 0 indicates deep coma. Lower scores correspond to deeper levels of sedation.

    Time frame: Day 1 for each period

  2. Electroencephalogram bispectrality index (BIS) monitoring

    BIS is the most widely used method for the continuous monitoring of sedation depth in clinical anesthesia. BIS values range from 0 to 100, where 100 represents complete wakefulness and 0 indicates complete cortical electrical inhibition.

    Time frame: Day 1 for each period

  3. Loss of eyelash reflex

    The eyelash reflex is a commonly used clinical method to assess the level of consciousness in patients. Gentle stimulation of the eyelashes with a cotton swab normally elicits a blink; absence of this response indicates loss of the eyelash reflex.

    Time frame: Day 1 for each period

  4. Modified Aldrete Scoring (Aldrete) Scale

    The Modified Aldrete Score is the most widely used standardized tool for assessing discharge readiness from post-anesthesia care unit (PACU). It evaluates five parameters: activity, respiration, blood pressure consciousness, and SpO₂. Ranging from 0 to 10, the higher the score, the better the quality of recovery.

    Time frame: Day 1 for each period

  5. Number of reported Adverse Events

    Safety and tolerability was assessed by the number of volunteers with adverse events.

    Time frame: 24 hours post-dose for each period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 3, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Nov 24, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07913048
Responsible party
Sponsor
First posted
Nov 3, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Nov 24, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 3, 2026

Study contacts

Wei Qi
Contact
qiw@kelun.com
028-82339360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KL0011034

Start the discussion